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Edited by Micheal R. BubbAbstract The unique myosin binding protein-c ‘‘motif’’ near the
N-terminus of myosin binding protein-C (MyBP-C) binds myo-
sin S2. Previous studies demonstrated that recombinant proteins
containing the motif and ﬂanking regions (e.g., C1C2) aﬀect thin
ﬁlament movement in motility assays using heavy meromyosin
(S1 plus S2) as the molecular motor. To determine if S2 is re-
quired for these eﬀects we investigated whether C1C2 aﬀects
motility in assays using only myosin S1 as the motor protein. Re-
sults demonstrate that eﬀects of C1C2 are comparable in both
systems and suggest that the MyBP-C motif aﬀects motility
through direct interactions with actin and/or myosin S1.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Muscle1. Introduction
Myosin binding protein-C (MyBP-C) has rapidly become
recognized as a novel modulator of striated muscle contrac-
tion. The cardiac isoform of MyBP-C (cMyBP-C) appears
important for normal physiological function of the heart as
well as in pathophysiological conditions since it is phosphory-
lated in response to inotropic stimuli and mutations in the
cMyBP-C gene (i.e., MYBP3) are a leading cause of inherited
cardiomyopathies [1]. Accumulating evidence indicates that
MyBP-C modulates contraction by limiting actomyosin inter-
actions so that cross-bridge cycling is slower in the presence of
MyBP-C than in its absence [2,3]. Slowing of crossbridge
kinetics by MyBP-C may account for the dramatic accelera-
tions observed in the time courses of stretch activation in myo-
cytes from cMyBP-C null mice [4] and in normalized elastance
of hearts from cMyBP-C deﬁcient mice [5].
Hypotheses for how MyBP-C slows actomyosin interactions
include a ‘‘tether’’ model in which MyBP-C binds to two sites
on myosin (i.e., to the S2 and light meromyosin (LMM) seg-
ments of myosin) and thereby restricts the movement of myo-
sin S2 relative to LMM [6]. According to this scheme the twoAbbreviations: MyBP-C, myosin binding protein-C; S1, Myosin sub-
fragment 1; S2, myosin subfragment 2; HMM, heavy meromyosin;
LMM, light meromyosin
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of the myosin heads such that extension of myosin cross-
bridges towards the thin ﬁlament is restricted. Alternatively,
the idea that the two binding sites function independently
has been suggested [7] and is supported by observations that
a recombinant protein containing the S2 binding site (i.e.,
C1C2) increased Ca2+-sensitivity of tension in permeabilized
myocytes from cMyBP-C null mice that lack endogenous
cMyBP-C (and therefore lack the second LMM binding site)
[8]. In addition, we recently found that C1C2 aﬀected actomy-
osin interactions in motility assays where S2 was present but
LMM was not [9]. However, eﬀects of C1C2 in that study
could not be attributed solely to interactions with myosin S2
since cosedimentation assays showed that C1C2 also bound
to actin.
In the present study, we investigated the extent to which
interactions with S2 contribute to eﬀects of C1C2 in motility
assays by using S1 motor domains (lacking S2) to generate
movement. Surprisingly, results show that myosin S2 is not re-
quired for the eﬀects of C1C2 on motility and instead suggest a
novel mechanism whereby interactions of C1C2 with actin
and/or myosin S1 slow crossbridge kinetics.2. Materials and methods
2.1. Protein preparation
All proteins and labeled actin were prepared as described [9]. Myosin
S1 was prepared by papain digestion of myosin (12.5 lg/ml, 10 min) in
the presence of 5 mMMgCl2 [10] or via digestion with a-chymotrypsin
(50 lg/ml, 10 min) in the presence of 1 mM EDTA [11]. In some cases,
papain S1 (P-S1) was further puriﬁed by gel ﬁltration to remove undi-
gested myosin (Fig. 1) [10,11]. P-S1 was added to a Sephacryl S-300
HR (Pharmacia Biotech, Piscataway, NJ) column equilibrated with
(in mM): 10 imidazole, 500 KCl, and 1 dithiothreitol, pH 7.4. The
column was run on a BioLogic LP system (Bio-Rad, Hercules, CA)
for 16 h (0.25 ml/min) and 3 ml fractions were collected. Fractions
containing S1 were pooled and used for motility assays. At the
start of each day of experiments a high speed centrifugation step
(500000 · g, 20 min, TLA 120.2 rotor in a Beckman Optima TLX
ultracentrifuge) was performed to remove ATP-insensitive heads [12].
This step was also eﬀective at removing undigested myosin regardless
of additional chromatography (Fig. 1) and was therefore routinely per-
formed prior to S1 use in motility or ATPase assays.
2.2. In vitro motility assays
Motility assays were performed essentially as described [9] except
temperature was 30 C. Nitrocellulose-coated slides were used in motil-
ity assays with chymotryptic (CT)-S1, whereas uncoated glass slides
were used with P-S1 because motility was found to be smoother and
more uniform on glass. Motility buﬀers also contained 0.3–0.6%
400cP methylcellulose to limit F-actin diﬀusion from the assay surface
[12]. A minimum of four experiments (slides) were performed for eachblished by Elsevier B.V. All rights reserved.
Fig. 1. SDS–PAGE of puriﬁed myosin and subfragments. L, protein
markers; 1, myosin; 2, HMM; 3, P-S1 pre-gel ﬁltration column; 4, P-S1
post column; 5, CT-S1 pre- high speed centrifugation to remove ATP-
insensitive heads; 6, CT-S1 post-high speed centrifugation. Positions of
myosin heavy chain (MHC) and S1 are indicated by arrows.
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analyzed per condition. Data were compared using ANOVA followed
by Bonferroni post hoc comparisons. Signiﬁcance was considered at
P < 0.05.
2.3. ATPase assays
Actin-activated ATPase rates of puriﬁed P-S1 were measured as de-
scribed [9] except 0.2 lM P-S1 and 5 lM F-actin were used. All assays
were performed at 22 C.3. Results
3.1. C1C2 inhibits F-actin ﬁlament sliding in acto-S1 motility
assays
Eﬀects of C1C2 on movement of rhodamine-phalloidin
(RhPh)-labeled F-actin ﬁlaments over coverslips coated with
P-S1 are shown in Fig. 2. Under control conditions in the ab-
sence of C1C2, P-S1 supported smooth, uniform movement of
F-actin (1.7 ± 0.4 lm/s). Filament speed and fraction of ﬁla-
ments motile were similar to that reported by others for P-S1
[13]. However, addition of 1 lM C1C2 signiﬁcantly slowedFig. 2. Speed and fraction of F-actin ﬁlaments moving over papain-
digested S1. Bars represent means ± S.D. Asterisks denote signiﬁcant
diﬀerence from control (0 lM C1C2), P < 0.05.motility and reduced the fraction of ﬁlaments moving. Move-
ment was stopped and indistinguishable from rigor at 5 lM
C1C2.
To exclude the possibility that eﬀects of C1C2 were due to
interactions with S2 present as a possible contaminant from
undigested myosin, P-S1 was further puriﬁed via gel ﬁltration
chromatography over Sephacryl S-300 HR resin. As shown in
Fig. 1, P-S1 contained undigested myosin prior to gel-ﬁltration
or high speed centrifugation to remove ATP-insensitive heads,
whereas myosin was not detected in gel-ﬁltered P-S1. Table 1
shows summary data for results of motility assays using gel-
puriﬁed P-S1. Mean speed of F-actin over gel-puriﬁed P-S1
was 1.2 ± 0.4 lm/s, slightly slower than for unﬁltered P-S1.
However, addition of C1C2 slowed gel-puriﬁed P-S1 to a sim-
ilar extent as unﬁltered P-S1 (Table 1), indicating that the ef-
fects of C1C2 to inhibit motility cannot be attributed to S2.
S1 can also be prepared by digestion of myosin with chy-
motrypsin (CT). Since CT-S1 diﬀers somewhat from P-S1
with respect to myosin heavy chain size, light chain content
and speed in motility assays [13], we investigated whether
eﬀects of C1C2 depended on the method of S1 preparation.
As shown in Table 1, motility over CT-S1 was not signiﬁ-
cantly diﬀerent from movement over gel-puriﬁed P-S1. How-
ever, C1C2 was again eﬀective at inhibiting ﬁlament sliding,
indicating that C1C2 eﬀects on motility do not depend on
method of S1 preparation.3.2. Dual eﬀects of C1C2 on reconstituted thin ﬁlament
motility over S1
We had previously shown that C1C2 exerted dual activating
and inhibitory eﬀects in motility assays using heavy meromyo-
sin (HMM) as the motor protein when reconstituted thin ﬁla-
ments containing troponin and tropomyosin were used instead
of labeled F-actin alone [9]. Eﬀects of C1C2 on Ca2+-regulated
motility of reconstituted thin ﬁlaments over P-S1 were there-
fore assessed. As shown in Fig. 3, addition of troponin and
tropomyosin to F-actin restored Ca2+-dependent activation
of motility, such that under control conditions ﬁlament move-
ment was stopped at low Ca2+ (pCa 9.0, Fig. 3A, 0 lM C1C2)
and activated at high Ca2+ (pCa 5.0, Fig. 3B, 0 lM C1C2).
Notably, we did not see augmentation of ﬁlament speed at
high Ca2+ (over that of unregulated F-actin, Fig. 2) as has been
reported when HMM is used as the molecular motor [12]. It is
unclear whether this diﬀerence can be attributed to the absence
of S2 or to other variables such as the isoform or proportion of
troponin and tropomyosin used [14]. However, under condi-
tions of high Ca2+, C1C2 was again eﬀective at slowing ﬁla-
ment sliding speed, albeit higher concentrations of C1C2
were required. At low Ca2+ (pCa 9.0), C1C2 biphasically acti-
vated and inhibited ﬁlament movement. These results are qual-
itatively similar to previous results using HMM and
demonstrate that interactions with myosin S2 are not required
for the dual eﬀects of C1C2 in Ca2+-regulated motility assays.3.3. C1C2 inhibits actin-activated ATPase rates of S1
To determine whether C1C2 aﬀects the enzyme activity of
acto-S1 in addition to its mechanical properties, eﬀects of
10 lM C1C2 on the actin-activated ATPase rates of puriﬁed
P-S1 in solution were measured. Similar to eﬀects of C1C2
on actin-activated ATPase rates of HMM [9], 10 lMC1C2 sig-
niﬁcantly inhibited acto-S1 ATPase rates compared to control
Fig. 3. Mean speed and fraction moving for reconstituted thin
ﬁlaments over papain-digested S1 at (A) pCa 9.0 and (B) pCa 5.0.
Bars represent means ± S.D. Asterisks indicate signiﬁcant diﬀerence
from control (0 lM C1C2), P < 0.05.
Table 1
Summary of motility data for F-actin movement over gel-puriﬁed
papain S1 (P-S1) and unﬁltered chymotryptic S1 (CT-S1)









0 1.2 ± 0.4 0.6 ± 0.1 1.5 ± 0.5 0.6 ± 0.2
0.1 ND ND 0.9 ± 0.2 0.4 ± 0.1
0.5 0.6 ± 0.4 0.5 ± 0.1 0.2 ± 0.1* 0.1 ± 0.1*
1 0.5 ± 0.3* 0.4 ± 0.3 0.2 ± 0.03* 0.2 ± 0.04*
2 0.3 ± 0.1* 0.2 ± 0.1* 0.2 ± 0.1* 0.2 ± 0.1*
Values are means ± S.D. ND, no data. Asterisks indicate signiﬁcant
diﬀerence from control (P < 0.05).
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fect P-S1 ATPase rates in the absence of actin (not shown).4. Discussion
The major ﬁnding from this study is that myosin S2 is not
required for eﬀects of the C1C2 domains of MyBP-C in motil-
ity assays. Results from assays using S1 as the molecular motor
recapitulated eﬀects of C1C2 using HMM (S1 plus S2) [9] andtherefore suggest that the C1C2 domains, including the unique
MyBP-C motif, aﬀect actomyosin contractile properties via a
novel mechanism not involving myosin S2.
Candidates for C1C2 binding in the absence of S2 include
actin and myosin S1 (and/or its light chains). In support of
the former, we previously demonstrated that C1C2 cosedi-
ments with F-actin or with reconstituted thin ﬁlaments under
conditions similar to those used here for motility assays [9].
In the present experiments, C1C2 also inhibited actin-activated
S1 ATPase rates in solution, but not intrinsic S1 ATPase rates,
further suggesting that interactions with actin, or possibly the
combination of actin and myosin S1, are important for eﬀects
of C1C2. By contrast, S1 alone did not compete for C1C2
binding in separate cosedimentation experiments [15], suggest-
ing that C1C2 binds weakly or not at all to myosin S1. Thus, it
is likely that eﬀects of C1C2 in motility assays are due primar-
ily to interactions with actin, although the possibility that
C1C2 binds to a combination of actin and myosin S1 cannot
be excluded.
The precise mechanism(s) by which binding of C1C2 to actin
and/or myosin S1 aﬀects cross-bridge kinetics is not known.
However, dual inhibitory and activating eﬀects of C1C2 on
Ca2+-regulated motility are consistent with the idea that
C1C2 stabilizes a strong cross-bridge binding state, thereby
promoting thin ﬁlament activation at low Ca2+ and slowing
sliding velocity at high Ca2+ [9]. Alternatively, dual activating
and inhibitory eﬀects of C1C2 may involve separate and dis-
tinct mechanisms. In either event, the present results exclude
myosin S2 as having an essential role in the mechanism(s) by
which C1C2 aﬀects motility.
Demonstration that S2 is not required for mechanical eﬀects
of C1C2 in motility assays raises the possibility that binding to
S2 is not required for contractile eﬀects of MyBP-C in sarco-
meres. However, it is notable that C1C2 localizes to A-bands
[15], presumably through S2 binding, and not to thin ﬁlaments
as suggested here. Therefore, the question arises as to whether
conditions exist where actin may compete with S2 for C1C2
binding. In this respect, phosphorylation of the motif may be
relevant since phosphorylation abolishes binding to S2 [16].
Alternatively, it is possible that actin and S2 do not compete,
but that C1C2 binds both actin and S2. According to this sce-
nario, binding to S2 might anchor the C1C2 domains near ac-
tive sites on actin or myosin S1. Consistent with this idea,
model ﬁts of structural data suggest that the N-terminus of
MyBP-C interacts with the thin ﬁlament [17]. Although thin
ﬁlament interactions with the C0 domain of cMyBP-C [18]
or a proline-alanine rich sequence at the N-terminus of
MyBP-C [17] have been suggested, it is possible that interac-
tions extend beyond these to include the C1C2 domains as
well. A remaining question, however, is whether the length
of the motif plus the two ﬂanking domains (C1 and C2) is suf-
ﬁcient to span an interﬁlament distance of 8–12 nm and there-
by permit binding to both S2 and actin. This may be plausible
based on dimensions of C1 and C2 obtained by nuclear mag-
netic resonance spectroscopy and on the ﬁnding that a portion
of the S2 binding site is located near the C-terminus of C2
[19,20]. It will therefore be of interest to determine the relative
position of the actin binding site and whether the length of the
intervening segment is suﬃcient to link the thin and thick ﬁla-
ments. If so, the N-terminal domains of MyBP-C, including
the MyBP-C motif, may aﬀect contractile function through
direct interactions with the thin ﬁlament.
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